OTC · Healthcare
BIOTRICITY INC. (BTCY)
As-reported financials and recent SEC filings for BIOTRICITY INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$13.8M
Net income
$-8.4M
Net margin
-61.1%
Diluted EPS
$-0.56
ROE
26.3%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $13.8M | $12.1M | $9.6M | $7.7M | $3.4M |
| Gross profit | $10.6M | $8.4M | $5.4M | $4.6M | $1.3M |
| Operating income | $-2.4M | $-8.8M | $-15.4M | $-16.7M | — |
| Net income | $-8.4M | $-14.1M | $-18.7M | $-29.1M | $-15.5M |
| Diluted EPS | $-0.56 | $-0.83 | $-1.13 | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
NT 10-K2026-06-29
View on EDGAR →DEF 14C2026-06-16
View on EDGAR →PRE 14C2026-05-29
View on EDGAR →SCHEDULE 13G/A2026-05-12
View on EDGAR →8-K2026-05-01
View on EDGAR →8-K2026-02-18
View on EDGAR →10-Q2026-02-11
View on EDGAR →SCHEDULE 13G/A2026-02-04
View on EDGAR →Largest Healthcare peers
Go deeper on BTCY
Search BIOTRICITY INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.